[Effect of lanreotide on prolactin level in patients with pituitary mixed tumors].
Acromegaly is a disease caused by a pituitary tumor (somatotropinoma) or by ectopic secretion of GH or IGF-1. About 15% of tumors secrete not only GH but PRL as well. Last time a lanreotide and an octreotide (the somatostatine analogues) are useful in the therapy of acromegaly. We observed the influence of the lanreotide on GH and prolactin. We noticed that the lanreotide caused not only serum level reduction of a growth hormone but also prolactine in patients with mixed pituitary tumors.
Wasko
R
R
Clinique d'Endocrinologie, Académie de Médecine de l'Université de Karol Marcinkowski de Poznan 60-355. Przybyszewskiego 49, Pologne.
Sawicka
J
J
Stachowiak
C
C
Kozak
W
W
Junik
R
R
Sowinski
J
J
D000172:Acromegaly / Q000188:drug therapy / Q000209:etiology*; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D013006:Growth Hormone / Q000378:metabolism; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000378:metabolism; D011388:Prolactin / Q000097:blood* / Q000378:metabolism; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D019382:Human Growth Hormone; D013004:Somatostatin; D011388:Prolactin; D013006:Growth Hormone